# 1 Fibrosis and liver inflammation are key regulators of $\alpha$ 1-acid

# 2 glycoprotein fucosylation

- 3 Carlos Oltmanns<sup>1,2,3,4</sup>, Birgit Bremer<sup>1,3</sup>, Laura Kusche<sup>1</sup>, Per Stål<sup>6</sup>, Robin Zenlander<sup>7</sup>,
- 4 Jan Tauwaldt<sup>1,2,3,4</sup>, Ingvar Rydén<sup>8</sup>, Peter Påhlsson<sup>\*8</sup>, Markus Cornberg<sup>\*1,2,3,4,5</sup>, Heiner
- 5 Wedemeyer\*<sup>1,3,5</sup>
- 6
- <sup>1</sup> Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School
   (MHH), Hannover, Germany
- 9 <sup>2</sup> Centre for Individualised Infection Medicine (CiiM), a joint venture between the Helmholtz
- 10 Centre for Infection Research (HZI) and Hannover Medical School (MHH). Hannover,
- 11 Germany
- <sup>3</sup> Cluster of Excellence Resolving Infection Susceptibility (RESIST; EXC 2155), Hannover
   Medical School, Hannover, Germany
- <sup>4</sup> TWINCORE, a joint venture between the Helmholtz-Centre for Infection Research (HZI) and
   the Hannover Medical School (MHH). Hannover, Germany
- <sup>5</sup> German Centre for Infection Research (DZIF), partner site Hannover-Braunschweig,
  Germany
- 18 <sup>6</sup> Department of Medicine, Huddinge, Karolinska Institutet; and Division of Hepatology,
- 19 Department of Upper GI diseases, Karolinska University Hospital; Stockholm, Sweden
- 20 <sup>7</sup> Department of Clinical Chemistry, Karolinska University Hospital; Department of Laboratory
- 21 Medicine, Karolinska Institutet; and Department of Medicine, Huddinge, Karolinska Institutet;
- 22 Stockholm, Sweden
- 23 <sup>8</sup> Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
- 24 \*contributed equally
- 25
- 26

## 27 Abstract

Background and Aims: There is an urgent need for new high-quality markers in the
early detection of hepatocellular carcinoma (HCC). Åström et al. suggested that S2bound α1-acid glycoprotein (AGP) might be a promising marker. Consequently, we
evaluated S2-bound AGP for a predictive advantage in the early detection of HCC.


32 Methods: In a retrospective case-control study of patients chronically infected with 33 hepatitis C virus (HCV) and treated with direct-acting antiviral agents (n=93), we 34 measured S2-bound AGP using the HepaCheC® ELISA kit (Glycobond AB, Linköping, SE) at treatment start, end of treatment and follow-up (maximum: 78 months). Patients 35 36 were retrospectively propensity score matched (1:2). 31 patients chronically infected 37 with HCV developed HCC after sustained virological response while 62 did not. In 38 addition, samples of HBV, MASLD and HCC from different etiologies patients were 39 measured.

Results: S2-bound AGP elevation in HCC patients was confirmed. However, we did
not observe a predictive advantage of S2-bound AGP in early detection of HCC during
treatment and follow-up. Interestingly, S2-bound AGP levels correlated with aspartate
aminotransferase (p=0.56, p=9.5x10<sup>-15</sup>) and liver elastography (p=0.67, p=2.2x10<sup>-16</sup>).
Of note, S2-bound AGP decreased in patients chronically infected with HCV after
treatment-induced clearance of HCV.

46 Conclusion: Fibrosis and liver inflammation are key regulators in the fucosylation of
47 AGP. The potential role of S2-bound AGP as a novel tumor marker requires further
48 investigation.

49 Key words: S2-bound AGP, Surveillance, HCC, Biomarker, HCV, HBV, MASLD,
50 Cancer, AST, Elastography

#### **Graphical abstract** 51



52

#### 53 Author contributions:

HW conceived the project and coordinated the analyses. CO, BB and HW designed 54 the experiments. CO, LK, JT, PP, IR, MC and HW drafted the manuscript. MC, PS, RZ 55 and HW were involved in recruitment of patients. JT was involved in creation of the 56 clinical cohort and BB helped acquiring the data. CO acquired and analyzed the data 57 supervised by HW. All authors read and approved the manuscript. 58

#### 59 Abbreviations:

60 A1AT: Alpha-1 antitrypsin, AFP: Alpha-fetoprotein, AFP-L3: Lectin-reactive alpha-61 fetoprotein, AGP: α1-acid glycoprotein, ALT: Alanine amino transferase, AST: Aspartate aminotransferase, DAA: Direct-acting antiviral agents, DCP: Des-gamma-62 63 carboxy prothrombin, GALAD: Gender, age, AFP-L3, AFP and DCP, HBV: Hepatitis B virus, HCC: Hepatocellular carcinoma, HCV: Hepatitis C virus, MASLD: Metabolic-64 dysfunction associated steatotic liver disease, PS: Propensity score, SVR: Sustained 65 virological response 66

### 67 Introduction

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-associated deaths worldwide [1]. We know that early detection of HCC can improve survival [2] [3]. Therefore, there is an urgent need to improve early detection [4]. As of today, ultrasound sonography with or without AFP is the gold standard for HCC surveillance [5]. Additional markers as AFP, AFP-L3 and DCP can improve sensitivity and specificity of HCC diagnosis. However, they do not allow an earlier diagnosis and their use has not been associated with an improved outcome [6] [7] [8].

75 Through the last decades, several groups showed that cancer development and 76 severe liver disease affect serum glycoproteins [9]. Since AFP, AFP-L3 and DCP fall 77 short of predicting HCC effectively, other glycoproteins have been studied extensively. 78 Comunale et al. studied the fucosylation of alpha-1-antitrypsin (A1AT) and 79 demonstrated that it is a potential biomarker candidate [10]. In contrast, Asazawa et al. studied fucosylated haptoglobin and showed a potentially higher sensitivity in 80 81 detecting HCC than AFP alone [11]. Despite these efforts, none of these markers could 82 meet the criteria for a high-quality predictive HCC marker and make it to the clinical 83 stage.

Therefore, Åström et al. aimed to find a new HCC biomarker for early detection of HCC.
They suggested that a reverse lectin based assay, measuring multifucosylated
oligosaccharides, could differentiate between HCC and cirrhotic or non-cirrhotic
hepatitis C virus (HCV) patients [12]. However, it remains unclear, whether S2-bound
α1-acid glycoprotein (AGP) shows a predictive advantage and whether S2-bound AGP
elevation is HCC specific or driven by inflammation and fibrosis.

We evaluated S2-bound AGP in a longitudinal retrospective case-control study consisting of patients, who underwent treatment of chronic hepatitis C virus infection with direct-acting antiviral agents (DAA). In addition, we demonstrate how liver inflammation and fibrosis affect S2-bound AGP levels in a real world setting. In the end, this study offers the opportunity to understand how inflammation and fibrosis might play a fundamental role in the fucosylation of glycoproteins.

### 97 Materials and Methods

#### 98 Study population and design

99 We collected plasma samples from overall 93 patients chronically infected with 100 hepatitis C virus. All patients were treated with DAAs since January 1, 2014. Thirty-101 one patients developed HCC after start of therapy with DAAs (HCV HCC cohort). In 102 contrast, 62 matched controls did not develop liver cancer during the follow-up period 103 (HCV Control cohort). All patients achieved sustained virological response (SVR) and 104 the majority of patients suffered from cirrhosis. Patients that were lost to follow-up or 105 did not achieve SVR (n=200), patients that did not have data available for the matching 106 variables (n=26) and patients that were excluded during the matching process (n=480) 107 were excluded from further analysis (Figure 1).

108 We took samples at therapy start, end of treatment and at the time of HCC diagnosis

109 (HCV HCC) or at the last available visit (HCV Control). All samples were collected in

110 the outpatient clinic of Hannover Medical School between January 1, 2014 and March

111 31, 2021. We received written consent from all patients in advance.

112 In addition, we measured samples from different liver diseases independent of HCV 113 infection. Three additional groups were measured, including patient chronically 114 infected with hepatitis B virus (HBV) (n=22), patients with metabolic dysfunction-115 associated steatotic liver disease (MASLD) (n=20) and patients with HCC of different 116 etiologies (n=31) (Suppl. table 1).

#### 117 Validation cohort

To validate our findings we analyzed a cohort of 173 patients from Sweden suffering from severe liver disease. One-hundred and two patients were diagnosed with liver cirrhosis whereas 71 patients were diagnosed with HCC. Etiologies of disease varied and most patients developed severe liver disease based on an HCV infection and/or high alcohol consumption. The HCC patients were either not treated for HCC (n=25), currently under treatment (n=23) or had completed the treatment (n=23).

#### 124 Cohort matching

We matched our 31 HCV HCC patients in a 1:2 propensity score (PS) matching with 62 HCV Control patients using R Statistical Software (Version 4.0.5.) and the Matchlt package [13]. In order to receive a robustly matched control cohort we chose nearest

- neighbor matching as the method of matching [14]. Our matching variables included
- sex, age, transient elastography, platelets and follow-up length.

#### 130 Sample preparation

- 131 Plasma was processed and then stored at a maximum temperature of -20° Celsius.
- 132 We measured all samples using the HepaCheC® ELISA kit (Glycobond AB, Linköping,
- 133 SE). The assay measures S2-bound AGP based on a reverse lectin ELISA [12]. We
- 134 measured all samples according to the standard protocol of the manufacturer.

#### 135 Statistical analysis

We analyzed our data using R Statistical Software (Version 4.0.5.) and GraphPad Prism (Version 8.3.1.). Therefore, we created all graphs with the packages *ggplot2* and *ggpubr* or within GraphPad Prism. As statistical test, we performed "Mann-Whitney-U test" for comparison of independent sample groups. In addition, we calculated all

- 140 correlations using Spearman's rank correlation since the investigated correlations were
- 141 non-linear. The graphical abstract was created using Biorender.com.

142

#### 143 **Results**

#### 144 Characteristics of the study cohort

Patient characteristics are shown in Table 1. In brief, patients chronically infected with HCV were middle-aged (HCV HCC: 59, HCV Control: 58.1) and mainly men (HCV HCC: 83.9% men, HCV Control 85.5% men). After PS matching, there were no differences between both groups regarding Child-Pugh score, HCV genotype, HCV-RNA, body mass index (BMI), platelets, aspartate aminotransferase (AST), alanine amino transferase (ALT), and albumin (Table 1A).

The HCV HCC group developed HCC after a median time of 28 months
(Supplementary Figure 1), whereas the Control group did not develop HCC during
follow-up (maximum follow-up: 78 months).

MASLD patients were overall older (MASLD: 67.6), whereas HBV and independent HCC patients showed younger age (HBV: 44.0, HCC: 50.1). Sex was equally distributed in the chronic HBV patients, MASLD patients were dominantly female (65% female), while HCC patients were mainly men (80.6%). AST and ALT were lower in the HCC patients than in the patients chronically infected with HCV but overall higher

than in the HBV and MASLD patients. Elastography was similar in chronic HCV and
HCC patients (Table 1B). Different etiologies of the independent HCC patients are
presented in Supplementary Table 1.

### 162 **S2-bound AGP is elevated in HCC and chronic HCV patients**

163 Confirming previous results, S2-bound AGP was increased in independent HCC 164 patients with 16/31 measured samples above the proposed cut-off (=1). In contrast, 165 S2-bound AGP was not elevated in chronic HBV (22/22 below cut-off) and MASLD 166 (18/20 below cut-off) patients. We observed a highly significant difference between 167 HCC patients and HBV or MASLD patients (HCC vs. HBV p<0.0001, HCC vs. MASLD 168 p=0.0005). In addition, MASLD patients showed significantly higher S2-bound AGP 169 levels than the HBV group (p=0.015).

- 170 Interestingly, patients chronically infected with HCV had highest S2-bound AGP levels,
- 171 significantly higher than in the HBV (p<0.0001) and MASLD group (p<0.0001). We did
- 172 not detect a significant difference in S2-bound AGP levels between HCC and chronic
- 173 HCV patients. Overall, 49/93 patients chronically infected with HCV showed increased
- 174 S2-bound AGP levels at baseline, which is similar to the HCC group (Figure 2).

### 175 S2-bound AGP correlates with AST and elastography

We next investigated to what extent markers of liver inflammation and fibrosis may correlate with S2-bound AGP. Indeed, both AST ( $\rho$ =0.56, p=9.5x10<sup>-15</sup>) and elastography ( $\rho$ =0.67, p=2.2x10<sup>-16</sup>) correlated with S2-bound AGP. Of note, a similar trend was found in subgroups including the patients chronically infected with HCV (AST:  $\rho$ =0.3, p=0.0047, elastography:  $\rho$ =0.36, p=0.00039) and HCC patients (AST:  $\rho$ =0.42, p=0.022) (Figure 3, Supplementary Figure 2).

### 182 S2-bound AGP correlates with AST and ALT in the validation cohort

To validate our findings we analyzed whether we could observe similar trends in the cohort of Swedish patients suffering from liver disease. Also here, we detected a correlation of S2-bound AGP with AST ( $\rho$ =0.35, p=3.1x10<sup>-6</sup>). In addition, there was also a weak correlation with ALT ( $\rho$ =0.21, p=6.2x10<sup>-3</sup>) (Figure 4).

#### 187 S2-bound AGP decreases in patients chronically infected with HCV after 188 treatment.

189 Building on top of these results, we analyzed the patients chronically infected with HCV 190 longitudinally, measuring S2-bound AGP levels at baseline, at end of antiviral 191 treatment and at long-term follow-up. The HCC and Control group both showed 192 increased S2-bound AGP levels at baseline. Furthermore, S2-bound AGP levels 193 decreased over time after successful treatment of the chronic HCV infection. We did 194 not detect any significant difference between the patients that developed HCC after 195 SVR and the patients from the Control group that did not develop HCC (HCC detection: 196 p=0.10). This hold true during the complete course of treatment and follow-up (Figure 197 5).

198

#### 199 Discussion

200 Despite decades of research effort, there is still a desperate need for predictive tumor 201 markers to diagnose HCC early and with high precision [5]. In this study, we followed 202 the hypothesis, that S2-bound AGP could be useful as a novel biomarker for early 203 detection of HCC. Indeed, we confirmed that S2-bound AGP levels are elevated in half 204 of the patients diagnosed with HCC, which is overall higher than traditional biomarkers, 205 including AFP. However and surprisingly, the frequency of S2-bound elevation was 206 similar in patients chronically infected with HCV. This suggests that non-specific 207 inflammation and fibrosis may drive S2-bound AGP elevation. Therefore, S2-bound 208 AGP is not a suitable candidate to predict development of hepatocellular carcinoma. 209 specifically in patients that achieved SVR after chronic HCV infection.

210 The concentration of S2-bound AGP was associated with AST levels in two 211 independent cohorts of patients. Although the association was evident in HCV, it was 212 not statistically significant in the HBV or MASLD subgroups, where the levels of AST 213 were lower than in the HCV group. However, we do not believe that the association of 214 S2-bound AGP and AST is a HCV specific effect, nor do we believe that HCV infection or replication are specific drivers of AGP fucosylation. Interestingly, there was a 215 216 significant reduction of S2-bound AGP levels after patients chronically infected with 217 HCV successfully cleared the virus. This is in line with previous reports of traditional 218 tumor markers that are also decreasing after SVR [15] [16]. However, this decline was

219 much more prominent in our data on S2-bound AGP, suggesting a direct effect of 220 chronic liver inflammation on fucosylation of AGP. Subsequently, most patients 221 showed normalized liver enzymes and decreased levels of S2-bound AGP at follow-222 up compared to baseline.

223 In addition, the entity of liver disease may also play an important role in the assessment 224 of new biomarkers. Whereas in patients chronically infected with HCV we observed 225 high levels of S2-bound AGP, there were significantly lower levels in patients that were 226 chronically infected with HBV or suffered from MASLD. At the same time, we observed 227 lower levels of inflammation indicated by AST and ALT in these patients. However, our 228 results are in line with previous findings on another tool for early detection of HCC, the 229 GALAD score. Best et al. provided evidence that the entity of liver disease influences 230 specificity and sensitivity of the GALAD score [17].

231 In the longitudinal cohort of patients chronically infected with HCV, S2-bound AGP did 232 not show a diagnostic advantage in early detection of the HCC. Based on a previous 233 study, Åström et al. suggested that S2-bound AGP could be specific for HCC [12]. While we see S2-bound AGP elevation in HCC patients in general, we could not see a 234 235 significant difference between patients chronically infected with HCV and recently 236 detected HCC and the HCV control group. Liver enzymes were elevated in the HCC 237 patients of different entities too, leading us to the conclusion that general inflammation 238 and fibrosis of the liver may influence previous study results.

239 Our results underline the challenges we are still facing in development of a high-quality 240 predictive tumor marker in the HCC field [18]. All previous studies have failed to 241 produce markers that can detect HCC reliably [19] [20]. Recently, Tayob et al. showed 242 in an American Phase 3 biomarker study that GALAD indeed increases sensitivity for 243 early detection of HCC but goes along with a significant false-positive rate of around 244 25 percent [8]. Therefore, it may be worth considering new approaches, such as using 245 patients' biological age as a predictive tool [21]. Finally, screening and evaluation of 246 more promising candidates but also combination of different approaches might 247 improve results for biomarker studies in the future.

Limits of our study include the relatively small number of patients in a retrospective study design from different cohorts. On the contrary, we were able to choose a wellmatched cohort, allowing us to compare patients chronically infected with HCV that developed HCC to those that did not develop cancer. The close follow-up of patients

after SVR allowed us to analyze pre-HCC-diagnosis-samples, bolstering our ability to
evaluate, whether there is a predictive advantage of S2-bound AGP.

254 S2-bound AGP is affected by liver inflammation and does not predict HCC reliably on its own. Since the challenge of early HCC detection seems to be more complex, future 255 256 research efforts should focus even more on a combination of markers [18]. Pattern 257 recognition in multi-omics approaches and high throughput technologies in patients 258 that develop HCC after chronic viral infection might play an important role. Fibrosis and 259 inflammation of the liver influence S2-bound AGP and may influence fucosylation in 260 other markers as well. Therefore, future studies on fucosylation should consider both 261 to discriminate better between HCC-specific and non-specific signals.

## 263 **Compliance with Ethical Standards**

#### 264 Informed consent and approval by the local ethics committee

- 265 This article does not contain any studies with animals performed by any of the authors.
- 266 The study protocol conformed to the ethical guidelines of the Declaration of Helsinki
- and the local ethics committee approved this study a priori (No. 9474\_BO\_K\_2020).
- 268 Informed consent was obtained from all individual participants included in the study.

#### 269 **Conflicts of interest:**

- 270 MC reports personal fees from Abbvie, personal fees from Falk Foundation, personal
- 271 fees from Gilead, personal fees from GlaxoSmithKline, personal fees from Jansen-
- 272 Cilag, personal fees from Merck/MSD, personal fees from Novartis, personal fees from
- 273 Roche, personal fees from Spring Bank Pharmaceuticals, and personal fees from
- 274 Swedish Orphan Biovitrum, outside the submitted work
- HW reports grants/research support and personal fees from Abbvie, Biotest AG and
  Gilead. He received personal fees from Aligos Therapeutics, Altimmune, Astra Zeneca,
  Bristol-Myers-Squibb, BTG Pharmaceuticals, Dicerna Pharmaceuticals, Enanta
  Pharmaceuticals, Dr. Falk Pharma, Falk Foundation, Intercept Pharmaceuticals,
  Janssen, Merck KGaA, MSD Sharp & Dohme GmbH, MYR GmbH, Norgine, Novartis,
- 280 Pfizer Pharma GmbH, Roche and Vir Biotechnology, outside the submitted work.
- 281 PS has received speaker fees from Merk Sharp & Dohme, Eisai, Roche and Albireo.
- 282 IR and PP are unpaid board members of Glycobond AB.
- 283 LK, JT, BB, CO and RZ have nothing to disclose.

### 284 Financial support statement:

This project is part of project A5 in the Collaborative Research Center 900 - Microbial Persistence and its Control. The Swedish Cancer Society supported PS. The project was partly financed by grants from Glycobond AB. CO was supported by a grant from the KlinStrucMed program of Hannover Medical School, funded by the Else Kröner-Fresenius Foundation.

### 291 **References**

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global
 Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide
 for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians 2021; 71:209-249.

[2] Singal A G, Zhang E, Narasimman M, Rich NE, Waljee AK, Hoshida Y et al. HCC
surveillance improves early detection, curative treatment receipt, and survival in
patients with cirrhosis: A meta-analysis. Journal of hepatology 2022; 77:128-139.

[3] Singal A G, Pillai A, Tiro J. Early Detection, Curative Treatment, and Survival Rates
 for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis.
 PLoS Medicine 2014; 11:e1001624.

- 301 [4] Nault J, Villanueva A. Biomarkers for Hepatobiliary Cancers. Hepatology 2020;302 73:115.
- 303 [5] Singal A G, Lampertico P, Nahon P. Epidemiology and surveillance for 304 hepatocellular carcinoma: New trends. Journal of hepatology 2020; 72:250-261.

[6] Lersritwimanmaen P, Nimanong S. Hepatocellular Carcinoma Surveillance: Benefit
 of Serum Alfa-fetoprotein in Real-world Practice. Euroasian Journal of Hepato Gastroenterology 2018; 8:83-87.

[7] Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A et al. Surveillance
Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in
Patients With Cirrhosis: A Meta-analysis. Gastroenterology (New York, N.Y. 1943)
2018; 154:1706-1718.e1.

[8] Tayob N, Kanwal F, Alsarraj A, Hernaez R, El-Serag HB. The Performance of AFP,
AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase
Biomarker Study in the United States. Clinical Gastroenterology and Hepatology
2023; 21:415-423.e4.

[9] Naitoh A, Aoyagi Y, Asakura H. Highly enhanced fucosylation of serum
glycoproteins in patients with hepatocellular carcinoma. Journal of gastroenterology
and hepatology 1999; 14:436-445.

[10] Comunale M A, Rodemich-Betesh L, Hafner J, Wang M, Norton P, Di Bisceglie
 AM et al. Linkage Specific Fucosylation of Alpha-1-Antitrypsin in Liver Cirrhosis and
 Cancer Patients: Implications for a Biomarker of Hepatocellular Carcinoma. PLoS ONE
 2010; 5:e12419.

[11] Asazawa H, Kamada Y, Takeda Y, Takamatsu S, Shinzaki S, Kim Y et al. Serum
 fucosylated haptoglobin in chronic liver diseases as a potential biomarker of
 hepatocellular carcinoma development. Clinical Chemistry and Laboratory Medicine
 (CCLM) 2015; 53:95-102.

medRxiv preprint doi: https://doi.org/10.1101/2023.11.14.23298443; this version posted November 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

[12] Åström E, Stål P, Zenlander R, Edenvik P, Alexandersson C, Haglund M et al. 327 Reverse lectin ELISA for detecting fucosylated forms of a1-acid glycoprotein 328 329 associated with hepatocellular carcinoma. PLoS ONE 2017; 12:e0173897.

330 [13] Ho D E, Imai K, King G, Stuart EA. Matchlt: Nonparametric Preprocessing for 331 Parametric Causal Inference. Journal of statistical software 2011; 42.

332 [14] Randolph J J, Austin KF, Manuel K, Balloun JL, Randolph JJ;, Falbe K; et al. A 333 Step-by-Step Guide to Propensity Score Matching in R. Practical Assessment, 334 Research, and Evaluation 2014; 19.

335 [15] Fouad R, Elsharkawy A, Abdel Alem S, El Kassas M, Alboraie M, Sweedy A et al. 336 Clinical impact of serum  $\alpha$ -fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals. European journal of 337 338 gastroenterology & hepatology 2019; 31:1129-1134.

- 339 [16] Nguyen K, Jimenez M, Moghadam N, Wu C, Farid A, Grotts J et al. Decrease of 340 Alpha-fetoprotein in Patients with Cirrhosis Treated with Direct-acting Antivirals. 341 Journal of Clinical and Translational Hepatology 2017; XX:1.
- 342 [17] Schotten C, Ostertag B, Sowa J, Manka P, Bechmann LP, Hilgard G et al. GALAD 343 Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic 344 Hepatitis B and C Patients. Pharmaceuticals (Basel, Switzerland) 2021; 14:735.
- 345 [18] Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. 346 Genes & Diseases 2020; 7:308-319.
- 347 [19] Nault J, Villanueva A. Biomarkers for Hepatobiliary Cancers. Hepatology 2020; 348 73:115.
- 349 [20] Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: 350 Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020; 9.
- 351 [21] Oltmanns C, Liu Z, Mischke J, Tauwaldt J, Mekonnen YA, Urbanek-Quaing M et 352 al. Reverse inflammaging: Long-term effects of HCV cure on biological age. J Hepatol 353 2023; 78:90-98.
- 354

### 356 Tables


**Table 1:** Baseline characteristics of analyzed patients. Subgroups include patients who developed HCC after SVR (HCV HCC) and matched controls (HCV Control) (A). In addition, we analyzed patients with chronic HBV infection, MASLD and HCC (B). For continuous parameters, mean values and standard deviations and for categorical parameters, absolute and relative numbers are shown.

Α	HCV HCC	HCV Control	P-value	Reference
n	31	62		
Age	59.0 (9.62)	58.1 (9.56)	-	
Sex				
т	26 (83.9%)	53 (85.5%)	-	
f	5 (16.1%)	9 (14.5%)		
HCV genotype			-	
1	22 (71.0%)	51 (82.2%)	-	
2	1 (3.2%)	1 (1.6%)	-	
3	7 (22.6%)	8 (12.9%)	-	
4	1 (3.2%)	1 (1.6%)	-	
Child-Pugh Score				
0	4 (12.9%)	11 (17.7%)	_	
Child A	21 (67.7%)	43 (69.4%)	-	
Child B	4 (12.9%)	8 (12.9%)	-	
Child C	1 (3.2%)	0		
Elastography (kPa)				
<14.5	5 (16.1%)	10 (16.1%)	-	0-14.5
14.5 - 25.0	3 (9.7%)	13 (21.0%)	_	0-14.0
>25.0	23 (74.2%)	39 (62.9%)	-	
Body mass index	26.8 (2.69)	27.9 (4.61)	0.14	18.5-24.9
Platelets (Tsd/µL)	97.9 (49.3)	96.1 (42.8)	0.87	160-370
INR (Ratio)	1.27 (0.334)	1.28 (0.348)	0.86	0.9-1.25
AST (U/L)	97.5 (58.2)	100 (55.3)	0.83	0-35 (m) 0-31 (f)
ALT (U/L)	92.7 (72.6)	101 (65.3)	0.61	0-45 (m) 0-34 (f)
Albumin (g/L)	33.3 (6.12)	35.5 (6.01)	0.10	35-52
HCV-RNA (IU/mL)	1,240,000 (2,010,000)	1,480,000 (1,760,000)	0.58	0

### 


В	HBV	MASLD	НСС	Reference
n	22	20	31	
Age	44.0 (11.6)	67.6 (11.7)	50.1 (11.4)	
Sex				
т	11 (50.0%)	7 (35.0%)	25 (80.6%)	
f	11 (50.0%)	13 (65.0%)	6 (19.4%)	
Elastography (kPa)	4.7 (1.8)	9.4 (3.3)	35.8 (23.5)	0-14.5
Platelets (Tsd/µL)	231 (52.5)	237 (58.9)	172 (99.4)	160-370
INR (Ratio)	1.04 (0.36)	1.01 (0.1)	1.28 (0.65)	0.9-1.25
AST (U/L)	26.2 (7.2)	48.6 (18.0)	79.3 (82.3)	0-35 (m) 0-31 (f)
ALT (U/L)	30.0 (12.9)	87.0 (40.5)	49.8 (47.3)	0-45 (m) 0-34 (f)

#### **Figures** 365



366 367





# S2-bound AGP in hepatitis and HCC patients

Figure 2: Concentration of S2-bound AGP in different groups of hepatitis and HCC 371 patients. For patients chronically infected with HCV (green), baseline results are 372 373 presented. Other groups included patients with chronic HBV infection (purple), patients 374 with metabolic dysfunction-associated steatotic liver disease (orange) and patients 375 with hepatocellular carcinoma (red). Shown are the median values for each group and 376 the maximum and minimum values.






Figure 3: Concentration of S2-bound AGP correlated with clinical parameters (AST 378 and elastography). Correlations are shown for all patients, including patients 379 380 chronically infected with HCV at baseline (A-B), patients chronically infected with HCV at baseline (C-D), and HCC patients from different etiologies (E-F). Spearman's Rank 381 382 Correlation was used to calculate all correlations.

383





- 385
- Figure 4: Concentration of S2-bound AGP correlated with clinical parameters (AST,
- ALT and Platelets) in a Swedish cohort of patients with severe liver disease.
- Spearman's Rank Correlation was used to calculate all correlations.




*Figure 5:* Longitudinal analysis of S2-bound AGP in patients chronically infected with 393 394 HCV. Patients that developed HCC after SVR (dark green) are compared with the PS-395 matched control group (light green). Shown are the median values for each time point 396 and the 95% confidence interval.

#### Supplementary material: 397

#### Supplementary Table 1: Etiology of HCC in HCC group. 398


Cause of HCC	Number of patients	Percentage
HBV	2	6.5%
НСЛ	6	19.4%
HDV	3	9.7%
MASLD	4	12.9%
Cryptogenic fibrosis / cirrhosis	2	6.4%
Hemochromatosis	1	3.2%
Ethyl toxic	6	19.4%
Ethyl toxic / viral hepatitis	3	9.7%
Ethyl toxic / MASLD	1	3.2%
Not available	3	9.7%

399



Supplementary Figure 1: Cumulative incidence of HCC in HCV HCC group after treatment 402 403 initiation.

404



407 Supplementary Figure 2: Concentration of S2-bound AGP correlated with clinical parameters (AST and elastography). Correlations are shown for MASLD (A-B) and 408 409 chronic HBV (C-D) patients. Spearman's Rank Correlation was used to calculate all 410 correlations.